Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density

Michele B. Kaufman, PharmD, BCGP  |  October 19, 2016

GENERIC_Drugs_500x270A recent study linked the use of proton pump inhibitors to changes in bone mineral density and an increased risk of developing osteoporosis. Also, denosumab proved effective at increasing bone mineral density in osteoporosis patients on glucocorticoid therapy.

Proton Pump Inhibitor Use Linked to Bone Mineral Density
A recent cross-sectional study evaluated the association between proton pump inhibitor (PPI) use and bone mineral density (BMD) in patients referred to the Gastroenterology Department of Kashan University of Medical Sciences, Kashan, Iran.1 The researchers investigated the relationship between PPI use and BMD in 80 patients age 20–45 years old, which included 31 men and 49 women, none with a history of hip fracture.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The follow-up period was a minimum of two years. Half of the patients received a PPI and half did not. All participants had their femur and posterior–anterior spine BMD quantified by dual-energy X-ray absorptiometry. The primary endpoints were femur and lumbar spine T-scores. Secondary endpoints were femur and lumbar spine Z-scores. Multi-variate linear regression analysis was adjusted for age, sex, body mass index and serum vitamin D levels, and used to test the potential associations between PPI use and BMD.

Mean femoral T-scores were significantly different between PPI users and non-users (-0.44 ± 1.11 vs. +0.19 ± 0.95, P = 0.007). Additionally, the frequency of femoral osteoporosis and osteopenia in the PPI-users group was significantly more than in the control group (P=0.04). However, the mean femoral Z-scores, lumbar spine T-score and lumbar spine Z-score were not statistically different between the PPI-user and the PPI-non-user groups. The study’s authors concluded that PPI use in individuals without osteoporosis risk factors had an increased risk of developing femoral osteoporosis and osteopenia.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Denosumab & Glucocorticoid-Induced Osteoporosis
In late August, Amgen reported the positive results of a Phase 3 study of denosumab in glucocorticoid-treated patients.2 This 24-week, international, multi-center, randomized, double-blind, double-dummy, active-controlled, parallel-group study was conducted in adults (n=795) receiving oral glucocorticoid therapy.

The study was designed to compare the safety and efficacy of treatment with 60 mg subcutaneous denosumab given every six months with the daily use of 5 mg oral risedronate. Two patient subpopulations were evaluated: 505 patients receiving continuous glucocorticoid therapy, defined as receiving more than 7.5 mg prednisone daily or its equivalent for more than three months and planning to continue treatment for at least six months; and 290 patients who were newly initiating glucocorticoid therapy, defined as receiving more than 7.5 mg prednisone daily or its equivalent for longer than three months and planning to continue treatment for at least six months. The primary endpoint was the percentage change from baseline in lumbar spine bone mineral density at Month 12 (to assess non-inferiority). Two secondary endpoints were the percentage change from baseline in lumbar spine and total hip bone mineral density (assessing superiority) at Month 12.

The study met all primary and secondary endpoints after 12 months. In patients who received continuing glucocorticoid therapy, treatment with denosumab led to greater bone mineral density increases compared with risedronate therapy at both the lumbar spine (4.4% vs. 2.3%) and total hip (2.1% vs. 0.6%). In patients who newly started glucocorticoid therapy, denosumab treatment led to greater bone mineral increases compared with risedronate at both the lumbar spine (3.8% vs. 0.8%) and at the total hip (1.7% vs. 0.2%).

Adverse events and serious adverse events were similar across treatment groups and consistent with the already known safety profile of denosumab.


Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Arj A, Razavi Zade M, Yavari M, et al. Proton pump inhibitors use and change in bone mineral density. Int J Rheum Dis. 2016 May 31. doi: 10.1111/1756-185X.12866. [Epub ahead of print]
  2. Amgen Inc. News release: Amgen announces positive top-line results from phase 3 study of Prolia (denosumab) in patients receiving glucocorticoid therapy. 2016 Aug 29.

Page: 1 2 | Multi-Page
Share: 

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)denosumabGlucocorticoid-Induced OsteoporosisGlucocorticoidsOsteoporosisproton pump inhibitor (PPI)

Related Articles

    Reading Rheum

    March 1, 2007

    Handpicked Reviews of Contemporary Literature

    New Insights into CPPD

    October 1, 2013

    Progress in research, outcomes, diagnosis, and treatment of calcium pyrophosphate dihydrate crystal deposition disease

    Denosumab vs. Zoledronate: An Analysis of Treatments for Low Bone Mineral Density in Patients with HIV

    May 9, 2022

    In a small study of men with low bone mineral density (BDM) living with HIV and taking anti-retroviral therapy, both zoledronate or denosumab were well tolerated and effective for bone mineral density of the lumbar spine and femoral neck.

    Denosumab May Work Better Than Risedronate for Steroid-Induced Osteoporosis

    April 26, 2018

    NEW YORK (Reuters Health)—The RANKL inhibitor denosumab is superior to the bisphosphonate risedronate in increasing bone-mineral density (BMD) at the lumbar spine in patients just starting or continuing steroid therapy, according to 12-month results of a 24-month randomized controlled study. “Glucocorticoid-induced osteoporosis is the most common form of secondary osteoporosis and increases the risk of…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences